Active ingredientAzvudineCat. No. P-A241-001CAS 1011529-10-4Family · Pharmaceutical analytical standards
Azvudine
A cytidine nucleoside analogue carrying an azide group and a fluorine atom, born from patents filed at Zhengzhou University: conditionally approved in China in 2021 against HIV and in 2022 against COVID-19. This family brings together the active ingredient and other impurities.
Did you know?In 2022 it became the first oral COVID antiviral developed in China to be approved in the country; years earlier it had already been identified in the laboratory as an inhibitor of the hepatitis C virus.
Go to the active ingredient →Active ingredientAzvudineCat. No. P-A241-001CAS 1011529-10-4
ImpurityAzvudine Impurity 1Cat. No. P-A241-003CAS 69123-94-0
Impurity2'Fluoro-2'-deoxyuridineCat. No. P-A241-004CAS 784-71-4
Impurity4'-Azido-2'-deoxy-2'-fluorocytidineCat. No. P-A241-005CAS 1145869-35-7
ImpurityAzvudine Impurity 2Cat. No. P-A241-006CAS 1596289-55-2
ImpurityAzvudine Impurity 3Cat. No. P-A241-007CAS 2648370-01-6
ImpurityAzvudine Impurity 4Cat. No. P-A241-008
ImpurityAzvudine Impurity 5Cat. No. P-A241-009
ImpurityAzvudine Impurity 6Cat. No. P-A241-010
ImpurityAzvudine Impurity 7Cat. No. P-A241-011No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.